Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cefepime/Zidebactam - Wockhardt

Next Previous
Drug Profile

Cefepime/Zidebactam - Wockhardt

Alternative Names: WCK-5222; Zaynich; Zidebactam/cefepime intravenous - Wockhardt

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wockhardt
  • Developer IQVIA; Wockhardt
  • Class Antibacterials; Azabicyclo compounds; Cephalosporins; Piperidines; Small molecules; Sulfoxides; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections; Urinary tract infections

Most Recent Events

  • 11 Apr 2025 Adverse event and pharmacokinetics data from the phase I trial in Urinary tract infections presented at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025 (ESCMID-2025)
  • 01 Apr 2025 The US FDA provides compassionate use approvals in the form of individual patient-specific expanded-access
  • 17 Feb 2025 Wockhardt completes a phase I trial in healthy volunteers (Monotherapy, Combination therapy) in USA (IV) (NCT06806995)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top